Univariate and multivariate analyses confirmed that the PFS in ROS1‐positive NSCLC patients was significantly associated with treatment patterns, and crizotinib treatment was more beneficial than chemotherapy. Here, ROS1 is linked to non-small cell lung carcinoma.